Antibodies against phosphorylcholine and protection against atherosclerosis, cardiovascular disease and chronic inflammation

References

• Frostegard J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11(1):117.
   PubMed Web of Science ®Google Scholar
• Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity [see comments]. N Engl J Med. 1989;320(14):915–924.
   PubMed Web of Science ®Google Scholar
• Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145(1):33–43.
   PubMed Web of Science ®Google Scholar
• Frostegard J, Wu R, Giscombe R, et al. Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb. 1992;12(4):461–467.
   PubMed Web of Science ®Google Scholar
• Frostegard J, Nilsson J, Haegerstrand A, et al. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci U S A. 1990;87(3):904–908.
   PubMed Web of Science ®Google Scholar
• Frostegard J, Huang YH, Ronnelid J, et al. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol. 1997;17(5):963–968.
   PubMed Web of Science ®Google Scholar
• Wan M, Hua X, Su J, et al. Oxidized but not native cardiolipin has pro-inflammatory effects, which are inhibited by Annexin A5. Atherosclerosis. 2014;235(2):592–598.
   PubMedGoogle Scholar
• Liu A, Ming JY, Fiskesund R, et al. Induction of dendritic cell-mediated T-cell activation by modified but not native low-density lipoprotein in humans and inhibition by annexin a5: involvement of heat shock proteins. Arterioscler Thromb Vasc Biol. 2015;35:197–205.
   PubMed Web of Science ®Google Scholar
• Lee S, Birukov KG, Romanoski CE, et al. Role of phospholipid oxidation products in atherosclerosis. Circ Res. 2012;111:778–799.
   PubMed Web of Science ®Google Scholar
• Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49(10):2230–2239.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Miyanohara A, Hartvigsen K, et al. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol. 2011;58(16):1715–1727.
   PubMed Web of Science ®Google Scholar
• van der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134(8):611–624.
   PubMed Web of Science ®Google Scholar
• Frostegard J, Svenungsson E, Wu R, et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 2005;52(1):192–200.
   PubMedGoogle Scholar
• Frostegard J, Wu R, Lemne C, et al. Circulating oxidized low-density lipoprotein is increased in hypertension. Clin Sci (Lond). 2003;105(5):615–620.
   PubMed Web of Science ®Google Scholar
• Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104(16):1887–1893.
   PubMed Web of Science ®Google Scholar
• Gora S, Maouche S, Atout R, et al. Phospholipolyzed LDL induces an inflammatory response in endothelial cells through endoplasmic reticulum stress signaling. Faseb J. 2010;24(9):3284–3297.
   PubMed Web of Science ®Google Scholar
• Miller YI, Tsimikas S. Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics. Curr Opin Lipidol. 2013;24(5):426–437.
   PubMed Web of Science ®Google Scholar
• Que X, Hung MY, Yeang C, et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature. 2018;558(7709):301–306.
   PubMed Web of Science ®Google Scholar
• Gearhart PJ, Johnson ND, Douglas R, et al. IgG antibodies to phosphorylcholine exhibit more diversity than their IgM counterparts. Nature. 1981;291(5810):29–34.
   PubMed Web of Science ®Google Scholar
• Briles DE, Forman C, Hudak S, et al. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med. 1982;156(4):1177–1185.
   PubMed Web of Science ®Google Scholar
• Szu SC, Clarke S, Robbins JB. Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine binding and relation to several types. Infect Immun. 1983;39(2):993–999.
   PubMed Web of Science ®Google Scholar
• Skovsted IC, Kerrn MB, Sonne-Hansen J, et al. Purification and structure characterization of the active component in the pneumococcal 22F polysaccharide capsule used for adsorption in pneumococcal enzyme-linked immunosorbent assays. Vaccine. 2007;25(35):6490–6500.
   PubMed Web of Science ®Google Scholar
• Binder CJ, Horkko S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med. 2003;9(6):736–743.
   PubMed Web of Science ®Google Scholar
• Agmon-Levin N, Bat-sheva PK, Barzilai O, et al. Antitreponemal antibodies leading to autoantibody production and protection from atherosclerosis in Kitavans from Papua New Guinea. Ann N Y Acad Sci. 2009;1173(1):675–682.
   PubMedGoogle Scholar
• Blank M, Bashi T, Lachnish J, et al. Helminths-based bi-functional molecule, tuftsin-phosphorylcholine (TPC), ameliorates an established murine arthritis. PLoS One. 2018;13(8):e0200615.
   PubMed Web of Science ®Google Scholar
• Shemer A, Kivity S, Shovman O, et al. Tuftsin-phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model. Clin Exp Immunol. 2018;193(2):160–166.
   PubMed Web of Science ®Google Scholar
• Salonen JT, Yla-Herttuala S, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339(8798):883–887.
   PubMed Web of Science ®Google Scholar
• Bergmark C, Wu R, de Faire U, et al. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol. 1995;15(4):441–445.
   PubMed Web of Science ®Google Scholar
• Puurunen M, Manttari M, Manninen V, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med. 1994;154(22):2605–2609.
   PubMedGoogle Scholar
• Wu R, Nityanand S, Berglund L, et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol. 1997;17(11):3159–3163.
   PubMed Web of Science ®Google Scholar
• Lehtimaki T, Lehtinen S, Solakivi T, et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol. 1999;19(1):23–27.
   PubMed Web of Science ®Google Scholar
• Wu R, de Faire U, Lemne C, et al. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension. 1999;33(1):53–59.
   PubMed Web of Science ®Google Scholar
• Karvonen J, Paivansalo M, Kesaniemi YA, et al. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation. 2003;108(17):2107–2112.
   PubMed Web of Science ®Google Scholar
• Su J, Georgiades A, Wu R, et al. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis. 2006;188(1):160–166.
   PubMed Web of Science ®Google Scholar
• Rontu R, Metso S, Jaakkola O, et al. Antibody titer against malondialdehyde-modified LDL compares with HDL cholesterol concentration in identifying angiographically verified coronary artery disease. Comparison of tests by ROC analysis. Clin Chem Lab Med. 2005;43(4):357–360.
   PubMed Web of Science ®Google Scholar
• Lopes-Virella MF, Virella G. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J Atheroscler Thromb. 2013;20(10):743–754.
   PubMed Web of Science ®Google Scholar
• Matsuura E, Kobayashi K, Hurley BL, et al. Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 2006;15(7):478–483.
   PubMed Web of Science ®Google Scholar
• Vaarala O, Alfthan G, Jauhiainen M, et al. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341(8850):923–925.
   PubMed Web of Science ®Google Scholar
• Sjogren P, Fredrikson GN, Samnegard A, et al. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J. 2008;29(18):2218–2226.
   PubMed Web of Science ®Google Scholar
• Fredrikson GN, Hedblad B, Berglund G, et al. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003;23(5):872–878.
   PubMed Web of Science ®Google Scholar
• Fredrikson GN, Anand DV, Hopkins D, et al. Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia. 2009;52(7):1426–1433.
   PubMed Web of Science ®Google Scholar
• Rahman M, Sing S, Golabkesh Z, et al. IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: regulation and underlying mechanisms. Clin Immunol. 2016;166-167:27–37.
   PubMed Web of Science ®Google Scholar
• Thiagarajan D, Frostegard AG, Singh S, et al. Human IgM antibodies to malondialdehyde conjugated with albumin are negatively associated with cardiovascular disease among 60-Year-Olds. J Am Heart Assoc. 2016;5(12). DOI:10.1161/JAHA.116.004415
   Web of Science ®Google Scholar
• Frostegard J. Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clin Immunol. 2010;134(1):47–54.
   PubMed Web of Science ®Google Scholar
• Gigante B, Leander K, Vikstrom M, et al. Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men. Atherosclerosis. 2014;236(2):394–399.
   PubMed Web of Science ®Google Scholar
• Caidahl K, Hartford M, Karlsson T, et al. IgM-phosphorylcholine autoantibodies and outcome in acute coronary syndromes. Int J Cardiol. 2013;167(2):464–469.
   PubMed Web of Science ®Google Scholar
• Eriksson UK, Sjoberg BG, Bennet AM, et al. Low levels of antibodies against phosphorylcholine in Alzheimer’s disease. J Alzheimers Dis. 2010;21(2):577–584.
   PubMed Web of Science ®Google Scholar
• de Faire U, Su J, Hua X, et al. Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J Autoimmun. 2010;34(2):73–79.
   PubMed Web of Science ®Google Scholar
• Sjoberg BG, Su J, Dahlbom I, et al. Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis. 2009;203(2):528–532.
   PubMed Web of Science ®Google Scholar
• Gronlund H, Hallmans G, Jansson JH, et al. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur J Cardiovasc Prev Rehabil. 2009;16(3):382–386.
   PubMedGoogle Scholar
• Su J, Hua X, Concha H, et al. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford). 2008;47(8):1144–1150.
   PubMed Web of Science ®Google Scholar
• Gronwall C, Akhter E, Oh C, et al. IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. Clin Immunol. 2012;142(3):390–398.
   PubMed Web of Science ®Google Scholar
• Gleer CA, Erbel C, Haeussler J, et al. Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease. Clin Res Cardiol. 2015;104(1):13–22.
   PubMed Web of Science ®Google Scholar
• Imhof A, Koenig W, Jaensch A, et al. Long-term prognostic value of IgM antibodies against phosphorylcholine for adverse cardiovascular events in patients with stable coronary heart disease. Atherosclerosis. 2015;243(2):414–420.
   PubMed Web of Science ®Google Scholar
• Sobel M, Yagi M, Moreno K, et al. Anti-phosphorylcholine IgM, an anti-inflammatory mediator, predicts peripheral vein graft failure: a prospective observational study. Eur J Vasc Endovasc Surg. 2019;57(2):259–266.
   PubMed Web of Science ®Google Scholar
• Iseme RA, McEvoy M, Kelly B, et al. A role for autoantibodies in atherogenesis. Cardiovasc Res. 2017;113(10):1102–1112.
   PubMed Web of Science ®Google Scholar
• Eichinger S, Kyrle PA, Kammer M, et al. Natural antibodies to oxidation-specific epitopes: innate immune response and venous thromboembolic disease. J Thromb Haemost. 2018;16(1):31–35.
   PubMed Web of Science ®Google Scholar
• Geller BJ, Mega JL, Morrow DA, et al. Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial. J Thromb Thrombolysis. 2014;37(3):310–316.
   PubMed Web of Science ®Google Scholar
• Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145(5):408–415.
   PubMed Web of Science ®Google Scholar
• Roman MJ, Salmon JE, Sobel R, et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol. 2001;87(5):663–6, A11.
   PubMed Web of Science ®Google Scholar
• Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2399–2406.
   PubMed Web of Science ®Google Scholar
• Kwee RM, van Oostenbrugge RJ, Hofstra L, et al. Identifying vulnerable carotid plaques by noninvasive imaging. Neurology. 2008;70(Issue 24, Part 2):2401–2409.
   PubMed Web of Science ®Google Scholar
• Mathiesen EB, Bonaa KH, Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the tromso study. Circulation. 2001;103(17):2171–2175.
   PubMed Web of Science ®Google Scholar
• Anania C, Gustafsson T, Hua X, et al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther. 2010;12(6):R214.
   PubMed Web of Science ®Google Scholar
• Thiagarajan D, Fiskesund R, Frostegard A, et al. Immunoglobulin G1 antibodies against phosphorylcholine are associated with protection in systemic lupus erythematosus and atherosclerosis: potential underlying mechanisms. ACR Open Rheumatol. 2020;2(6):344–356.
   PubMedGoogle Scholar
• Fiskesund R, Su J, Bulatovic I, et al. IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL. Results Immunol. 2012;2:13–18.
   PubMedGoogle Scholar
• Thiagarajan D, Oparina N, Lundstrom S, et al. IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. Sci Rep. 2020;10(1):11010.
   PubMed Web of Science ®Google Scholar
• Samal SK, Qureshi AR, Rahman M, et al. Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality. Clin Exp Immunol. 2020;201(1):94–104.
   PubMed Web of Science ®Google Scholar
• Dai L, Debowska M, Lukaszuk T, et al. Phenotypic features of vascular calcification in chronic kidney disease. J Intern Med. 2020;287(4):422–434.
   PubMed Web of Science ®Google Scholar
• Ajeganova S, Andersson MLE, Frostegard J, et al. Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events. Arthritis Res Ther. 2021;23(1):201.
   PubMed Web of Science ®Google Scholar
• Ajeganova S, Ehrnfelt C, Alizadeh R, et al. Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset–a prospective cohort study. Rheumatology (Oxford). 2011;50(10):1785–1793.
   PubMed Web of Science ®Google Scholar
• Ajeganova S, Fiskesund R, de Faire U, et al. Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study. Clin Exp Rheumatol. 2011;29:942–950.
   PubMed Web of Science ®Google Scholar
• Nguyen TG, McKelvey KJ, March LM, et al. Aberrant levels of natural IgM antibodies in osteoarthritis and rheumatoid arthritis patients in comparison to healthy controls. Immunol Lett. 2016;170:27–36.
   PubMed Web of Science ®Google Scholar
• Wilde B, Slot M, van Paassen P, et al. Phosphorylcholine antibodies are diminished in ANCA-associated vasculitis. Eur J Clin Invest. 2015;45:686–691.
   PubMed Web of Science ®Google Scholar
• Ohori J, Jimura T, Kurono Y. Role of Phosphorylcholine-Specific Immunoglobulin M in acute upper respiratory tract infections. Ann Otol Rhinol Laryngol. 2019;128:111S–116S.
   PubMed Web of Science ®Google Scholar
• Kankaanpaa J, Sampi M, Bloigu R, et al. IgA antibodies to phosphocholine associate with long-term cardiovascular disease risk. Atherosclerosis. 2018;269:294–300.
   PubMed Web of Science ®Google Scholar
• Brown M, Schiffman G, Rittenberg MB. Subpopulations of antibodies to phosphocholine in human serum. J Immunol. 1984;132:1323–1328.
   PubMed Web of Science ®Google Scholar
• Scott MG, Shackelford PG, Briles DE, et al. Human-igg subclasses and their relation to carbohydrate antigen immunocompetence. Diagnostic Clinical Immunology. 1988;5:241–248.
   PubMedGoogle Scholar
• Goldenberg HB, McCool TL, Weiser JN. Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. J Infect Dis. 2004;190:1254–1263.
   PubMed Web of Science ®Google Scholar
• Buhlin K, Gustafsson A, Pockley AG, et al. Risk factors for cardiovascular disease in patients with periodontitis. Eur Heart J. 2003;24:2099–2107.
   PubMed Web of Science ®Google Scholar
• Blaizot A, Vergnes JN, Nuwwareh S, et al. Periodontal diseases and cardiovascular events: meta-analysis of observational studies. Int Dent J. 2009;59:197–209.
   PubMed Web of Science ®Google Scholar
• Schenkein HA, Gunsolley JC, Best AM, et al. Antiphosphorylcholine antibody levels are elevated in humans with periodontal diseases. Infect Immun. 1999;67:4814–4818.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.
   PubMed Web of Science ®Google Scholar
• Rudikoff S, Potter M. Size differences among immunoglobulin heavy chains from phosphorylcholine-binding proteins. Proc Natl Acad Sci U S A. 1976;73:2109–2112.
   PubMed Web of Science ®Google Scholar
• Fiskesund R, Steen J, Amara K, et al. Naturally occurring human phosphorylcholine antibodies are predominantly products of affinity-matured B cells in the adult. J Immunol. 2014;192:4551–4559.
   PubMed Web of Science ®Google Scholar
• Thiagarajan D, Lundstrom SL, Pershagen G, et al. Antibodies against phosphorylcholine and malondialdehyde during the first two years of life. J Immunol. 2020;205:2109–2116.
   PubMed Web of Science ®Google Scholar
• Chen X, Gustafsson S, Whitington T, et al. A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia. Hum Mol Genet. 2018;27:1809–1818.
   PubMed Web of Science ®Google Scholar
• Xu Q, Dietrich H, Steiner HJ, et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb. 1992;12:789–799.
   PubMed Web of Science ®Google Scholar
• Freigang S, Horkko S, Miller E, et al. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol. 1998;18:1972–1982.
   PubMed Web of Science ®Google Scholar
• Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A. 1995;92:821–825.
   PubMed Web of Science ®Google Scholar
• Caligiuri G, Khallou-Laschet J, Vandaele M, et al. Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol. 2007;50:540–546.
   PubMed Web of Science ®Google Scholar
• Faria-Neto JR, Chyu KY, Li X, et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis. 2006;189:83–90.
   PubMed Web of Science ®Google Scholar
• Aprahamian TR, Zhong X, Amir S, et al. The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model. Int J Parasitol. 2015;45:203–207.
   PubMed Web of Science ®Google Scholar
• Chen Y, Khanna S, Goodyear CS, et al. Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J Immunol. 2009;183:1346–1359.
   PubMed Web of Science ®Google Scholar
• McCullagh K, Lewis MG. Spontaneous arteriosclerosis in the wild African elephant. Its relation to the disease in man. Lancet. 1967;2:492–495.
   PubMed Web of Science ®Google Scholar
• Samal SK, Frobert O, Kindberg J, et al. Potential natural immunization against atherosclerosis in hibernating bears. Sci Rep. 2021;11:12120.
   PubMed Web of Science ®Google Scholar
• Sun J, Lundstrom SL, Zhang B, et al. IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors. Atherosclerosis. 2018;268:36–48.
   PubMed Web of Science ®Google Scholar
• Lindeberg S, Berntorp E, Nilsson-Ehle P, et al. Age relations of cardiovascular risk factors in a traditional Melanesian society: the Kitava Study. Am J Clin Nutr. 1997;66:845–852.
   PubMed Web of Science ®Google Scholar
• Frostegård J, Tao W, Georgiades A, et al. Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea. Nutr Metab (Lond). 2007;4(1):7.
   PubMedGoogle Scholar
• Frostegard J, Tao W, Rastam L, et al. Antibodies against phosphorylcholine among new guineans compared to swedes: an aspect of the hygiene/missing old friends hypothesis. Immunol Invest. 2017;46(1):59–69.
   PubMed Web of Science ®Google Scholar
• Al-Riyami L, Harnett W. Immunomodulatory properties of ES-62, a phosphorylcholine-containing glycoprotein secreted by Acanthocheilonema viteae. Endocrine, metabolic & immune disorders drug targets. Endocrine, Metabolic & Immune Disorders Drug Targets. 2012;12(1):45–52.
   PubMedGoogle Scholar
• Pery P, Petit A, Poulain J, et al. Phosphorylcholine-bearing components in homogenates of nematodes. Eur J Immunol. 1974;4(9):637–639.
   PubMed Web of Science ®Google Scholar
• Grabitzki J, Ahrend M, Schachter H, et al. The PCome of Caenorhabditis elegans as a prototypic model system for parasitic nematodes: identification of phosphorylcholine-substituted proteins. Mol Biochem Parasitol. 2008;161(2):101–111.
   PubMed Web of Science ®Google Scholar
• Harkins KM, Stone AC. Ancient pathogen genomics: insights into timing and adaptation. J Hum Evol. 2015;79:137–149.
   PubMed Web of Science ®Google Scholar
• Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299(6710):1259–1260.
   PubMed Web of Science ®Google Scholar
• Rook GA, Martinelli R, Brunet LR. Innate immune responses to mycobacteria and the downregulation of atopic responses. Curr Opin Allergy Clin Immunol. 2003;3(5):337–342.
   PubMed Web of Science ®Google Scholar
• Rook GA. Hygiene hypothesis and autoimmune diseases. Clin Rev Allergy Immunol. 2012;42(1):5–15.
   PubMed Web of Science ®Google Scholar
• Versini M, Jeandel PY, Bashi T, et al. Unraveling the Hygiene Hypothesis of helminthes and autoimmunity: origins, pathophysiology, and clinical applications. BMC Med. 2015;13:81.
   PubMed Web of Science ®Google Scholar